Breakthrough Victoria is investing $800,000 in Diag-Nose.io Medical (DNM), a Melbourne based company improving research into drug treatments by monitoring chronic respiratory disease progression, which can potentially improve health outcomes for millions of people worldwide.
THE INVESTMENT
Investment Type | Seed |
Investment Vehicle | Convertible Note |
BV Investment | $800,000 |
WHAT IS DIAG-NOSE.io?
Diag-Nose Medical (DNM) is a Melbourne-based company focused on enhancing research into drug treatments for chronic respiratory diseases (CRDs). Founded in 2020, DNM is pioneering advancements in respiratory healthcare by focusing on the ‘unified airway’; the biological relationship between the lungs and nasal passages.
The company is particularly known for its flagship product, RhinoMAP, which employs proprietary protein chemistry and artificial intelligence (AI) to analyze biological subtypes of CRDs. This innovative approach allows for faster and more precise treatment decisions, ultimately reducing costs and improving patient outcomes for millions globally.
THE PROBLEM
Chronic respiratory diseases are a significant global health challenge, affecting over 450 million people and resulting in approximately four million deaths annually. Current treatment methods exhibit high failure rates, exceeding 30 per cent, often leading to trial-and-error approaches that yield limited efficacy and adverse events. Existing methods for measuring treatment efficacy and disease progression heavily rely on subjective data interpretation from imaging techniques such as X-rays and CT scans, as well as breath analysis and lung sounds. This complexity complicates the understanding of patient outcomes and hinders effective research and development of CRD drugs.
THE SOLUTION
DNM addresses these challenges by utilising a patented nasal swab device to collect samples, which are then analyzed through the RhinoMAP platform. This AI-powered biomarker analytics tool facilitates drug efficacy measurement, prediction, and long-term diagnostic recommendations. Initially targeting research applications, DNM aims to lower regulatory barriers while generating essential data for broader use cases, including drug development and patient response prediction. The company has established a robust network of key opinion leaders (KOLs) and early adopters, crucial for its growth as an early stage medtech entity.
IMPACT FOR VICTORIA
Thanks to Breakthrough Victoria’s $800,000 investment DNM expect to bolster local job creation—adding four new positions in Victoria—and expand manufacturing capabilities at its Melbourne facility.
This investment not only aims to enhance DNM's product offerings but also positions Victoria as a leader in the medtech sector. By fostering innovation in respiratory healthcare, DNM has the potential to significantly improve health outcomes both locally and globally.